Autohome Inc. (ATHM) Reaches $105.80 High on May, 14; Nektar Therapeutics (NKTR) Sentiment Is 1.19

May 14, 2018 - By Adrian Erickson

Nektar Therapeutics (NASDAQ:NKTR) Logo

Nektar Therapeutics (NKTR) investors sentiment decreased to 1.19 in Q4 2017. It’s down -0.21, from 1.4 in 2017Q3. The ratio is negative, as 119 active investment managers opened new or increased stock positions, while 100 decreased and sold holdings in Nektar Therapeutics. The active investment managers in our database now hold: 150.36 million shares, up from 148.76 million shares in 2017Q3. Also, the number of active investment managers holding Nektar Therapeutics in top ten stock positions increased from 5 to 11 for an increase of 6. Sold All: 18 Reduced: 82 Increased: 54 New Position: 65.




The stock of Autohome Inc. (NYSE:ATHM) reached all time high today, May, 14 and still has $112.14 target or 6.00% above today’s $105.80 share price. This indicates more upside for the $12.42B company. This technical setup was reported by Barchart.com. If the $112.14 PT is reached, the company will be worth $745.32 million more. The stock increased 1.68% or $1.745 during the last trading session, reaching $105.795. About 199,523 shares traded. Autohome Inc. (NYSE:ATHM) has risen 162.88% since May 14, 2017 and is uptrending. It has outperformed by 151.33% the S&P500.

The stock increased 5.15% or $4.095 during the last trading session, reaching $83.535. About 811,895 shares traded. Nektar Therapeutics (NKTR) has risen 347.01% since May 14, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

More important recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Investorplace.com which released: “3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies …” on May 11, 2018, also Bizjournals.com published article titled: “Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs”, Streetinsider.com published: “Nektar Therapeutics (NKTR) Misses Q1 EPS by 69c, Miss on Revenues” on May 10, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) was released by: Seekingalpha.com and their article: “Merck Is Inexpensive – Cramer’s Lightning Round (5/7/18)” with publication date: May 08, 2018.

Cormorant Asset Management Llc holds 12.49% of its portfolio in Nektar Therapeutics for 2.00 million shares. Camber Capital Management Llc owns 3.35 million shares or 9.79% of their US portfolio. Moreover, First Light Asset Management Llc has 5.76% invested in the company for 351,741 shares. The New York-based Duquesne Family Office Llc has invested 5.52% in the stock. Bridger Management Llc, a New York-based fund reported 1.37 million shares.

Since January 1, 0001, it had 0 buys, and 21 insider sales for $88.95 million activity.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $14.32 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Among 12 analysts covering Autohome Inc (NYSE:ATHM), 8 have Buy rating, 2 Sell and 2 Hold. Therefore 67% are positive. Autohome Inc had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by UBS given on Wednesday, October 7. CLSA reinitiated the stock with “Underperform” rating in Monday, February 22 report. The firm has “Buy” rating given on Thursday, August 10 by Benchmark. The company was downgraded on Tuesday, June 28 by Credit Suisse. The company was initiated on Thursday, October 29 by Citigroup. On Tuesday, November 14 the stock rating was upgraded by CLSA to “Buy”. Benchmark maintained it with “Buy” rating and $76.0 target in Wednesday, November 8 report. The stock of Autohome Inc. (NYSE:ATHM) has “Outperform” rating given on Friday, November 6 by Credit Agricole. As per Tuesday, January 2, the company rating was initiated by Citigroup. JP Morgan initiated Autohome Inc. (NYSE:ATHM) on Tuesday, February 23 with “Neutral” rating.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.